The FDA’s recent decision allowing Precigen to bypass certain accelerated approval and confirmatory trial requirements for a rare disease therapy signals potential shifts in regulatory flexibility. While this sets a precedent for rare disease drug development pathways, broader applicability remains uncertain. The move highlights evolving FDA stances on balancing expedited access with clinical evidence standards, impacting how future rare disease biologics might be reviewed.